REG - Burning Rock Biotech - Admission to Trading on the London Stock Exchange

Burning Rock BiotechAnnouncement

01/11/2022 10:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221101:nRSA9015Ea&default-theme=true

RNS Number : 9015E  Burning Rock Biotech Limited  01 November 2022

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR
INDIRECTLY, IN OR INTO OR FROM AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN OR ANY
OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE UNLAWFUL.

BURNING ROCK BIOTECH LIMITED - Admission to Trading on the London Stock
Exchange

1 November 2022

Neither this announcement, nor anything contained herein, nor anything
contained in the prospectus (the "Prospectus") referred to herein shall form
the basis of, or be relied upon in connection with, any offer or commitment
whatsoever in any jurisdiction. Investors should not subscribe for or purchase
any securities referred to in this announcement except solely on the basis of
the information contained in the Prospectus, including the risk factors set
out therein, published in connection with the admission (the "Admission") of
the Company's American depositary shares (the "ADSs") to the standard listing
segment of the Official List of the FCA and to trading on the Main Market of
London Stock Exchange plc (the "LSE") by way of a direct listing (the "Direct
Listing"). A copy of the Prospectus dated 27 October 2022 is available for
inspection on the Company's website at  http://ir.brbiotech.com/
(http://ir.brbiotech.com/) .

Admission to Trading on the London Stock Exchange

London, 1 November 2022: Burning Rock Biotech Limited (NASDAQ: BNR, the
"Company" or "Burning Rock"), announces that, further to its announcement on
27 October 2022, its ADSs have today been admitted to the standard listing
segment of the Official List of the FCA and to trading on the Main Market of
the LSE under the ticker "BNR".

Burning Rock's ADSs will continue to be listed and traded on the Nasdaq Global
Market, with those ADSs being fully fungible with the ADSs listed on the LSE.
Custodial and depositary links have been established between Euroclear,
Clearstream and DTC to facilitate the cross-market transfers of the ADSs
associated with secondary market trading.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via
science, focuses on the application of next generation sequencing (NGS)
technology in the field of precision oncology. Its business consists of i)
NGS-based therapy selection testing for late-stage cancer patients, and ii)
cancer early detection, which has moved beyond proof-of-concept R&D into
the clinical validation stage.

For more information about Burning Rock, please visit: www.brbiotech.com.

Enquiries:

Contact: IR@brbiotech.com

 

Important Legal Information

The information contained in this announcement is for background purposes only
and does not purport to be full or complete, nor does this announcement
constitute or form part of any invitation or inducement to engage in
investment activity. No reliance may be placed by any person for any purpose
on the information contained in this announcement or its accuracy, fairness or
completeness. The contents of this announcement are not to be construed as
legal, financial or tax advice.

This announcement is not for release, publication or distribution, directly or
indirectly, in or into Australia, Canada, South Africa or Japan or in any
other jurisdiction where, or to any person to whom, to do so would constitute
a violation of applicable law or regulation.

These materials do not constitute or form part of any offer or invitation to
sell or issue, or any solicitation of any offer to purchase or subscribe for,
any ADSs or any other securities, nor shall it (or any part of it), or the
fact of its distribution, form the basis of, or be relied on in connection
with, any contract therefore.

This announcement may include forward-looking statements, which are based on
current expectations and projections about future events. These statements may
include, without limitation, any statements preceded by, followed by or
including words such as "target", "believe", "expect", "aim", "intend", "may",
"anticipate", "estimate", "plan", "project", "will", "can have", "likely",
"should", "would", "could" and any other words and terms of similar meaning or
the negative thereof. These forward-looking statements are subject to risks,
uncertainties and assumptions about Burning Rock and its subsidiaries. In
light of these risks, uncertainties and assumptions, the events in the
forward-looking statements may not occur. Past performance cannot be relied
upon as a guide to future performance and should not be taken as a
representation that trends or activities underlying past performance will
continue in the future. No representation or warranty is made or will be made
that any forward-looking statement will come to pass. The forward-looking
statements in this announcement speak only as at the date of this
announcement.

Burning Rock expressly disclaims any obligation or undertaking to update,
review or revise any forward-looking statements contained in this announcement
and disclaims any obligation to update its view of any risks or uncertainties
described herein or to publicly announce the results of any revisions to the
forward-looking statements made in this announcement, whether as a result of
new information, future developments or otherwise, except as required by law.

The information in this announcement is subject to change. Persons viewing
this announcement should ensure that they fully understand and accept the
risks set out in the Prospectus.

Unless otherwise indicated, market, industry and competitive position data are
estimates (and accordingly, approximate) and should be treated with caution.
Such information has not been audited or independently verified, nor has the
Group ascertained the underlying economic assumptions relied upon therein.
Certain data in this announcement, including financial, statistical, and
operating information has been rounded. As a result of the rounding, the
totals of data presented in this announcement may vary slightly from the
actual arithmetic totals of such data.

For the avoidance of doubt, the contents of the Company's website are not
incorporated by reference into, and do not form part of, this announcement.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  LISEANFFESAAFEA